vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and Repay Holdings Corp (RPAY). Click either name above to swap in a different company.

Repay Holdings Corp is the larger business by last-quarter revenue ($78.6M vs $45.1M, roughly 1.7× Amarin Corp plc). Amarin Corp plc runs the higher net margin — -23.3% vs -178.3%, a 155.0% gap on every dollar of revenue. On growth, Amarin Corp plc posted the faster year-over-year revenue change (7.0% vs 0.4%). Over the past eight quarters, Repay Holdings Corp's revenue compounded faster (-1.3% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

Repay Holdings Corp is a leading payment technology provider delivering integrated end-to-end payment processing solutions for businesses across North America. Its offerings include credit/debit card processing, ACH transfer services, POS system integrations and digital payment tools, serving retail, healthcare, automotive and e-commerce segments to help clients streamline transaction workflows and boost operational efficiency.

AMRN vs RPAY — Head-to-Head

Bigger by revenue
RPAY
RPAY
1.7× larger
RPAY
$78.6M
$45.1M
AMRN
Growing faster (revenue YoY)
AMRN
AMRN
+6.6% gap
AMRN
7.0%
0.4%
RPAY
Higher net margin
AMRN
AMRN
155.0% more per $
AMRN
-23.3%
-178.3%
RPAY
Faster 2-yr revenue CAGR
RPAY
RPAY
Annualised
RPAY
-1.3%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
RPAY
RPAY
Revenue
$45.1M
$78.6M
Net Profit
$-10.5M
$-140.1M
Gross Margin
74.2%
Operating Margin
35.5%
-182.2%
Net Margin
-23.3%
-178.3%
Revenue YoY
7.0%
0.4%
Net Profit YoY
33.0%
-3304.1%
EPS (diluted)
$-1.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
RPAY
RPAY
Q1 26
$45.1M
Q4 25
$49.2M
$78.6M
Q3 25
$49.7M
$77.7M
Q2 25
$72.7M
$75.6M
Q1 25
$42.0M
$77.3M
Q4 24
$62.3M
$78.3M
Q3 24
$42.3M
$79.1M
Q2 24
$67.5M
$74.9M
Net Profit
AMRN
AMRN
RPAY
RPAY
Q1 26
$-10.5M
Q4 25
$-1.2M
$-140.1M
Q3 25
$-7.7M
$-6.4M
Q2 25
$-14.1M
$-102.3M
Q1 25
$-15.7M
$-7.9M
Q4 24
$-48.6M
$-4.1M
Q3 24
$-25.1M
$3.2M
Q2 24
$1.5M
$-4.1M
Gross Margin
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
47.1%
74.2%
Q3 25
44.7%
74.4%
Q2 25
69.2%
75.7%
Q1 25
59.8%
75.9%
Q4 24
-15.4%
76.3%
Q3 24
38.5%
77.8%
Q2 24
63.4%
78.2%
Operating Margin
AMRN
AMRN
RPAY
RPAY
Q1 26
35.5%
Q4 25
-12.9%
-182.2%
Q3 25
-22.4%
-3.9%
Q2 25
-22.0%
-138.7%
Q1 25
-39.9%
-4.7%
Q4 24
-84.3%
-1.5%
Q3 24
-59.5%
-0.9%
Q2 24
-0.8%
-4.6%
Net Margin
AMRN
AMRN
RPAY
RPAY
Q1 26
-23.3%
Q4 25
-2.5%
-178.3%
Q3 25
-15.6%
-8.3%
Q2 25
-19.4%
-135.2%
Q1 25
-37.4%
-10.3%
Q4 24
-78.0%
-5.3%
Q3 24
-59.4%
4.1%
Q2 24
2.3%
-5.4%
EPS (diluted)
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
$0.00
$-1.68
Q3 25
$-0.02
$-0.08
Q2 25
$-0.03
$-1.15
Q1 25
$-0.04
$-0.09
Q4 24
$-0.12
$-0.04
Q3 24
$-0.06
$0.03
Q2 24
$0.00
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
RPAY
RPAY
Cash + ST InvestmentsLiquidity on hand
$307.8M
$115.7M
Total DebtLower is stronger
$280.1M
Stockholders' EquityBook value
$484.4M
Total Assets
$645.8M
$1.2B
Debt / EquityLower = less leverage
0.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
RPAY
RPAY
Q1 26
$307.8M
Q4 25
$302.6M
$115.7M
Q3 25
$286.6M
$95.7M
Q2 25
$298.7M
$162.6M
Q1 25
$281.8M
$165.5M
Q4 24
$294.2M
$189.5M
Q3 24
$305.7M
$168.7M
Q2 24
$306.7M
$147.1M
Total Debt
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
$280.1M
Q3 25
$279.5M
Q2 25
$279.0M
Q1 25
$497.6M
Q4 24
$496.8M
Q3 24
$496.2M
Q2 24
$435.6M
Stockholders' Equity
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
$459.3M
$484.4M
Q3 25
$458.9M
$616.9M
Q2 25
$464.9M
$633.7M
Q1 25
$473.7M
$755.7M
Q4 24
$486.2M
$761.3M
Q3 24
$531.4M
$754.7M
Q2 24
$551.9M
$815.4M
Total Assets
AMRN
AMRN
RPAY
RPAY
Q1 26
$645.8M
Q4 25
$670.8M
$1.2B
Q3 25
$659.8M
$1.3B
Q2 25
$670.1M
$1.4B
Q1 25
$655.7M
$1.5B
Q4 24
$685.3M
$1.6B
Q3 24
$750.6M
$1.6B
Q2 24
$799.9M
$1.5B
Debt / Equity
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
0.58×
Q3 25
0.45×
Q2 25
0.44×
Q1 25
0.66×
Q4 24
0.65×
Q3 24
0.66×
Q2 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
RPAY
RPAY
Operating Cash FlowLast quarter
$23.3M
Free Cash FlowOCF − Capex
$23.2M
FCF MarginFCF / Revenue
29.6%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$90.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
$15.3M
$23.3M
Q3 25
$-12.7M
$32.2M
Q2 25
$16.6M
$33.1M
Q1 25
$-12.5M
$2.5M
Q4 24
$-13.3M
$34.3M
Q3 24
$-2.4M
$60.1M
Q2 24
$-2.7M
$31.0M
Free Cash Flow
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
$23.2M
Q3 25
$32.1M
Q2 25
$33.0M
Q1 25
$2.4M
Q4 24
$34.0M
Q3 24
$59.8M
Q2 24
$30.5M
FCF Margin
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
29.6%
Q3 25
41.3%
Q2 25
43.6%
Q1 25
3.0%
Q4 24
43.5%
Q3 24
75.6%
Q2 24
40.7%
Capex Intensity
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
0.1%
Q3 25
0.2%
Q2 25
0.1%
Q1 25
0.2%
Q4 24
0.3%
Q3 24
0.3%
Q2 24
0.6%
Cash Conversion
AMRN
AMRN
RPAY
RPAY
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
18.52×
Q2 24
-1.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

RPAY
RPAY

Sales Channel Directly To Consumer$69.4M88%
Other$6.8M9%
Sales Channel Through Intermediary$2.3M3%

Related Comparisons